Celldex Therapeutics Number of Employees 2010-2022 | CLDX

Celldex Therapeutics number of employees from 2010 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Celldex Therapeutics Annual Number of Employees
2021 134
2020 125
2019 130
2018 137
2017 197
2016 210
2015 199
2014 161
2013 129
2012 112
2011 103
2010 100
2009 93
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.301B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $166.663B 10.14
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.600B 16.73
Biohaven Pharmaceutical Holding (BHVN) United States $10.272B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.442B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.38
Emergent Biosolutions (EBS) United States $1.534B 6.57
Myovant Sciences (MYOV) United Kingdom $1.224B 0.00
Zymeworks (ZYME) Canada $0.317B 0.00
Gelesis Holdings (GLS) United States $0.111B 0.00
Ambrx Biopharma (AMAM) United States $0.100B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00